US$ 23.27
bpc-157 adverse effects humans case reports Where the current evidence on stands, on both sides BPC-157 Risks for Musculoskeletal Injuries
Description
Akram, M

(2018) "BPC 157 and Standard Angiogenic Growth Factors: Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing" Current Pharmaceutical Design Gwyer et al
however, BPC-157-specific studies should be described according to the exact VEGF or VEGFR2 endpoint actually measured, and the existing published evidence tends to emphasize VEGFR2-associated rather than VEGF-transcriptional observations

The human brain is extraordinarily good at identifying a narrative

Treating both at once can lead to better results